232 related articles for article (PubMed ID: 28677499)
1. Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals.
Lin X; Ammosova T; Kumari N; Nekhai S
Curr Pharm Des; 2017; 23(28):4122-4132. PubMed ID: 28677499
[TBL] [Abstract][Full Text] [Related]
2. Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.
Kumari N; Iordanskiy S; Kovalskyy D; Breuer D; Niu X; Lin X; Xu M; Gavrilenko K; Kashanchi F; Dhawan S; Nekhai S
Antimicrob Agents Chemother; 2014 Nov; 58(11):6558-71. PubMed ID: 25155598
[TBL] [Abstract][Full Text] [Related]
3. Iron chelators ICL670 and 311 inhibit HIV-1 transcription.
Debebe Z; Ammosova T; Jerebtsova M; Kurantsin-Mills J; Niu X; Charles S; Richardson DR; Ray PE; Gordeuk VR; Nekhai S
Virology; 2007 Oct; 367(2):324-33. PubMed ID: 17631934
[TBL] [Abstract][Full Text] [Related]
4. Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.
Debebe Z; Ammosova T; Breuer D; Lovejoy DB; Kalinowski DS; Kumar K; Jerebtsova M; Ray P; Kashanchi F; Gordeuk VR; Richardson DR; Nekhai S
Mol Pharmacol; 2011 Jan; 79(1):185-96. PubMed ID: 20956357
[TBL] [Abstract][Full Text] [Related]
5. Small molecules targeted to a non-catalytic "RVxF" binding site of protein phosphatase-1 inhibit HIV-1.
Ammosova T; Platonov M; Yedavalli VR; Obukhov Y; Gordeuk VR; Jeang KT; Kovalskyy D; Nekhai S
PLoS One; 2012; 7(6):e39481. PubMed ID: 22768081
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV effect of iron chelators: different mechanisms involved.
van Asbeck BS; Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ
J Clin Virol; 2001 Feb; 20(3):141-7. PubMed ID: 11166663
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinases as therapeutic targets for HIV-1 infection.
Rice AP
Expert Opin Ther Targets; 2016 Dec; 20(12):1453-1461. PubMed ID: 27797603
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 by curcumin A, a novel curcumin analog.
Kumari N; Kulkarni AA; Lin X; McLean C; Ammosova T; Ivanov A; Hipolito M; Nekhai S; Nwulia E
Drug Des Devel Ther; 2015; 9():5051-60. PubMed ID: 26366056
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1.
Tyagi M; Iordanskiy S; Ammosova T; Kumari N; Smith K; Breuer D; Ilatovskiy AV; Kont YS; Ivanov A; Üren A; Kovalskyy D; Petukhov M; Kashanchi F; Nekhai S
Retrovirology; 2015 Jul; 12():63. PubMed ID: 26178009
[TBL] [Abstract][Full Text] [Related]
10. 1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription.
Ammosova T; Platonov M; Ivanov A; Kont YS; Kumari N; Kehn-Hall K; Jerebtsova M; Kulkarni AA; Uren A; Kovalskyy D; Nekhai S
Br J Pharmacol; 2014 Nov; 171(22):5059-75. PubMed ID: 25073485
[TBL] [Abstract][Full Text] [Related]
11. Role of cellular iron and oxygen in the regulation of HIV-1 infection.
Nekhai S; Kumari N; Dhawan S
Future Virol; 2013 Mar; 8(3):301-311. PubMed ID: 23678366
[TBL] [Abstract][Full Text] [Related]
12. A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication.
Massari S; Daelemans D; Barreca ML; Knezevich A; Sabatini S; Cecchetti V; Marcello A; Pannecouque C; Tabarrini O
J Med Chem; 2010 Jan; 53(2):641-8. PubMed ID: 19958026
[TBL] [Abstract][Full Text] [Related]
13. Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells.
Lacombe B; Morel M; Margottin-Goguet F; Ramirez BC
J Virol; 2016 Dec; 90(23):10972-10980. PubMed ID: 27681137
[TBL] [Abstract][Full Text] [Related]
14. Curcumin and its analogues: a potential natural compound against HIV infection and AIDS.
Prasad S; Tyagi AK
Food Funct; 2015 Nov; 6(11):3412-9. PubMed ID: 26404185
[TBL] [Abstract][Full Text] [Related]
15. HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation.
Zhang HS; Ruan Z; Sang WW
J Cell Physiol; 2011 Dec; 226(12):3385-91. PubMed ID: 21344388
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis.
Georgiou NA; van der Bruggen T; Oudshoorn M; Hider RC; Marx JJ; van Asbeck BS
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():91-6. PubMed ID: 11886438
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics.
de la Fuente C; Maddukuri A; Kehn K; Baylor SY; Deng L; Pumfery A; Kashanchi F
Curr HIV Res; 2003 Apr; 1(2):131-52. PubMed ID: 15043199
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.
Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS
J Infect Dis; 2000 Feb; 181(2):484-90. PubMed ID: 10669330
[TBL] [Abstract][Full Text] [Related]
19. Stages of HIV replication and targets for therapeutic intervention.
Tözsér J
Curr Top Med Chem; 2003; 3(13):1447-57. PubMed ID: 14529520
[TBL] [Abstract][Full Text] [Related]
20. Curcumin inhibits HIV-1 by promoting Tat protein degradation.
Ali A; Banerjea AC
Sci Rep; 2016 Jun; 6():27539. PubMed ID: 27283735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
